Tumor tissues vary considerably in their microenvironment, and the existence of other cell types can influence the ability of the immune system to infiltrate and attack tumor cells. As promising new therapies evolve, there is an increasing need to identify cancer immunotherapy biomarkers to guide their appropriate application.
NGS can provide careful analysis of the cancer genome, and efficiently assess the tumor milieu as a real-time, highly sensitive monitor of immune marker expression in response to tumor growth or treatment. NGS analysis can be used to characterize the immune cell repertoire, identify various cell populations in the microenvironment, and comprehensively quantify gene expression of thousands of targets simultaneously.
Studies of epigenetic alterations in cancer, such as aberrant methylation and altered transcription factor binding, can provide insight into important tumorigenic pathways. As altered methylation often activates or silences genes, changes in the epigenome can affect gene expression and the rate of cancer progression.
NGS and microarray technologies can detect altered methylation patterns and other epigenetic changes in cancer.
RNA analysis may help to identify aspects of the tumor microenvironment that can influence the effectiveness of checkpoint immunotherapies, such as inductive and inhibitory cytokines, and local recruitment of other cells types that can inhibit the T-cell response.
RNA-Seq and HLA typing using NGS are powering the Immatics target discovery platform to develop personalized T-cell therapy programs.Read Interview
Cancer researchers need simple-to-use bioinformatics applications to gain insights from complex genomic data. BaseSpace Cohort Analyzer allows biologists and researchers to make important discoveries without specialized bioinformatics skills. The retrospective analysis of clinical trial data can help inform future cancer research and drug development programs.
Illumina offers several library preparation and sequencing options with access to data analysis options for tumor microenvironment analysis. Streamlined workflows and flexible kit configurations accommodate multiple study designs.
Approximately 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*
Click on the below to view products for each workflow step.
Nextera Flex for Enrichment uses a fast, user-friendly workflow. On-bead tagmentation chemistry is combined with a simplified, single hybridization protocol to reduce total workflow time.TruSeq DNA Exome
TruSeq DNA Exome is a cost-effective library preparation and exome enrichment solution.TruSeq RNA Exome
The TruSeq RNA Exome library prep kit provides a low-cost solution for analyzing human RNA isolated from limited or low-quality samples, including FFPE.
Transcriptome profiling of hundreds to tens of thousands of single cells in a single experiment.TruSeq DNA Methylation Kit
Whole-genome bisulfite sequencing libraries from as little as 50 ng DNA.TruSight Oncology 500
Assay targeting multiple variant types, including tumor mutational burden (TMB) and microsatellite instability (MSI), even from low-quality samples.
*Data calculations on file, Illumina, Inc, 2015.